Vor Biopharma Inc. (VOR)
| Market Cap | 569.96M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -2.45B |
| Shares Out | 38.72M |
| EPS (ttm) | -431.80 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 630,114 |
| Open | 14.50 |
| Previous Close | 14.53 |
| Day's Range | 13.50 - 14.76 |
| 52-Week Range | 2.62 - 65.80 |
| Beta | 2.08 |
| Analysts | Buy |
| Price Target | 66.63 (+352.65%) |
| Earnings Date | Nov 13, 2025 |
About VOR
Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. The company offers the Vor Bio platform, a technology platform for the treatment of acute myeloid leukemia (AML) and other blood cancers. It develops tremtelectogene empogeditemcel (trem-cel), a genome-edited hematopoietic stem and progenitor allogeneic donor product candidate to treat acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and other blood cancers; trem-cel in combination with Mylotarg to treat patients in VBP101, which is in phase 1 / 2;... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for VOR stock is "Buy." The 12-month stock price target is $66.63, which is an increase of 352.65% from the latest price.
News
Vor Bio Appoints RA Capital's Andrew Levin, M.D., Ph.D., and Forbion's Wouter Joustra to Board of Directors
BOSTON, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Vor Biopharma Inc. (Nasdaq: VOR), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announce...
Vor Bio Announces $150 Million Private Placement
BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it has entered into a se...
Vor Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Multiple Late-Stage Data Readouts Reinforce Telitacicept's Broad Potential Across Autoimmune Diseases Expansion of Executive Leadership and Board Strengthens Global Development Capabilities
Vor Biopharma Secures $100 Million Offering After Reporting Efficacy In Kidney Disease Trial
Vor Biopharma Inc. (NASDAQ:VOR) on Tuesday priced an underwritten public offering of 10 million shares at $10.00 per share.
Vor Bio Announces Pricing of Public Offering of $100 Million of Common Stock
BOSTON, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Vor Biopharma Inc. (Nasdaq: VOR), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announced the p...
Vor Bio Announces Proposed Public Offering of $100 Million of Common Stock
BOSTON, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Vor Biopharma Inc. (Nasdaq: VOR) (Vor Bio), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today annou...
Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China
Treatment with telitacicept for 39 weeks resulted in a rapid, clinically meaningful, and statistically significant reduction in proteinuria, with a favorable safety profile
Vor Bio to Participate in Upcoming Investor Conferences
BOSTON, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will participate in t...
Vor Bio Appoints Jeremy Sokolove, M.D. as Chief Medical Officer
BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of Jeremy Sok...
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on October 15, 2025, th...
Telitacicept Demonstrates Sustained Efficacy and Favorable Safety Profile in 48-Week China Phase 3 Open-Label Extension Generalized Myasthenia Gravis Data
Telitacicept delivered consistent quality-of-life improvement across both treatment and placebo crossover arms 100% of patients on telitacicept for 48 weeks achieved ≥2-point Myasthenia Gravis Activit...
Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sjögren's Disease
CAMBRIDGE, Mass., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it will host a...
Vor Bio Announces Late-Breaking Oral Presentation of China Phase 3 IgA Nephropathy Clinical Study at American Society of Nephrology's Kidney Week 2025
CAMBRIDGE, Mass., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that clinical data ...
Vor Bio Announces Publication of China Phase 3 Study of Telitacicept in Systemic Lupus Erythematosus in The New England Journal of Medicine
Trial met primary endpoint achieving statistically significant improvement in disease activity, with 67.1% of patients responding with telitacicept versus 32.7% with placebo Dual inhibition of BAFF a...
Telitacicept Demonstrates Clinically Meaningful and Statistically Significant Impact on ESSDAI Compared to Placebo in Late-Breaking China Phase 3 Results in Primary Sjögren's Disease at ACR 2025
Telitacicept met primary and all secondary endpoints, demonstrating clinically meaningful improvements in disease activity versus placebo ~71.8% of patients receiving telitacicept 160mg achieved ≥3-po...
Vor Bio Announces Late-Breaking Poster Presentation of Phase 3 Primary Sjögren's Disease Clinical Study at ACR Convergence 2025
BOSTON, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that clinical data from the ...
Vor Biopharma: Transformed Company Is A High Risk Buy On Autoimmune Disease Promise
Vor Biopharma has rebounded from near-delisting by securing global rights (ex-China) to telitacicept, a promising autoimmune therapy. VOR's telitacicept targets multi-billion dollar autoimmune markets...
Vor Bio Appoints Navid Z. Khan, Ph.D.
CAMBRIDGE, Mass., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announced the a...
Results of China Phase III Clinical Study of Telitacicept for Generalized Myasthenia Gravis Selected for Oral Presentation at 2025 AANEM Annual Meeting
YANTAI, China , Sept. 17, 2025 /PRNewswire/ -- RemeGen (688331.SH/09995.HK) announced that the 48-week open-label extension (OLE) data from China Phase III clinical study of telitacicept (RC18, brand ...
Vor Bio Announces Oral Presentation of 48-Week China Phase 3 Generalized Myasthenia Gravis Clinical Study at AANEM
CAMBRIDGE, Mass., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that 48-week clini...
Vor Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum
CAMBRIDGE, Mass., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will parti...
Vor Bio Appoints Adi Osovsky, S.J.D. as General Counsel
CAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of...
Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for IgA Nephropathy
Results reinforce telitacicept's potential across multiple autoimmune diseases Data anticipated to be presented at an upcoming medical conference CAMBRIDGE, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Vo...
Vor Bio Rallies On Strong Data For Autoimmune Drug Candidate
Vor Bio VOR stock is trading higher on Wednesday with a session volume of 10.83 million compared to the average volume of 17.99 million, as per data from Benzinga Pro.
Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for Primary Sjögren's Disease with Telitacicept, a Dual BAFF/APRIL Inhibitor
Phase 3 results position telitacicept as potential best-in-disease profile in primary Sjögren's disease Telitacicept demonstrated a favorable safety profile Vor evaluating timing of global Phase 3 cli...